Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Mass Balance Study of [14C]HRS-1893
NCT07656779Phase 1Not yet recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-1893 in cardiomyopathy, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Total radioactivity ratio of whole blood/plasma, Time to reach maximum concentration and 9 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HRS-1893
03
Conditions
cardiomyopathy
Beyond the preview
Go deeper on NCT07656779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656779.